Abstract | INTRODUCTION: Recent insight into the pathogenesis of ulcerative colitis have led to the development of new treatment options. A better understanding of IBD pathophysiology has progressively led to a more frequent use of immunosuppressants and biologics. AREAS COVERED: EXPERT OPINION:
Ulcerative colitis is a chronic condition mainly affecting young people in their more productive age, and determining high indirect costs to the patient and to society. Thus, there is a need for optimizing and renewing our traditional therapeutic approach to UC, and new therapies beyond conventional treatment options possibly aiming to change the poor clinical course of many patients with ulcerative colitis. Keeping in mind this potentially new therapeutic scenario, there are some critical areas in which early and more diffuse use of conventional and emerging new immunomodulators is advocated.
|
Authors | Sandro Ardizzone, Andrea Cassinotti, Roberto de Franchis |
Journal | Expert opinion on emerging drugs
(Expert Opin Emerg Drugs)
Vol. 17
Issue 4
Pg. 449-67
(Dec 2012)
ISSN: 1744-7623 [Electronic] England |
PMID | 23163556
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Immunologic Factors
- Immunosuppressive Agents
|
Topics |
- Age Factors
- Animals
- Colitis, Ulcerative
(drug therapy, physiopathology)
- Drug Design
- Humans
- Immunologic Factors
(therapeutic use)
- Immunosuppressive Agents
(therapeutic use)
- Time Factors
|